United Kingdom Diabetic Retinopathy Market Insight
The United Kingdom Diabetic Retinopathy Market is growing at an 7.81%CAGR, driven by rising diabetes, NHS screening expansion, and AI, anti-VEGF, and laser advancements improving outcomes.
United Kingdom Diabetic Retinopathy Market Insights Forecasts to 2035
- The United Kingdom Diabetic Retinopathy Market Size Was Estimated at USD 454.6Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 7.81% from 2025 to 2035
- The United Kingdom Diabetic Retinopathy Market Size is Expected to Reach USD 964.2Million by 2035
Notable Insights for United Kingdom Diabetic Retinopathy Market
- By treatment type, anti-VEGF injections dominate, accounting for approximately 55–60% share, due to strong efficacy in preventing vision loss.
- By diagnostic type, retinal imaging and fund us photography hold around 60–65% share, driven by NHS screening programs and AI-enabled diagnostics.
- Nearly 25–30% of diabetic patients in the UK show early signs of diabetic retinopathy, highlighting strong screening demand.
- Around 50–60% of diagnosed patients undergo regular monitoring through hospital-based ophthalmology services, supporting early intervention strategies.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Diabetic Retinopathy Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Diabetic Retinopathy Market
- Roche
- Novartis
- Bayer
- Regeneron Pharmaceuticals
- Johnson & Johnson
- Pfizer
- Carl Zeiss Meditec
- Topcon Corporation
- Others
Recent Developments:
- In October 2025: UCL researchers, supported by Diabetes UK and Moorfields Eye Charity, identified LRG1 protein as early trigger of diabetic retinopathy; pre-clinical drug targeting LRG1 aims to prevent disease progression.
- In June 2024: The Scottish LENS trial showed fenofibrate slowed progression of early diabetic retinopathy in NHS patients, supporting repurposed oral therapy for preventing vision loss in diabetes.
Market Segmentation:
United KingdomDiabetic Retinopathy Market, By Treatment Type
- Anti-VEGF Therapy
- Laser Photocoagulation
- Corticosteroid Implants
- Vitrectomy Surgery
- Others
United Kingdom Diabetic Retinopathy Market, By Disease Stage
- Mild non-proliferative
- Moderate non-proliferative
- Severe non-proliferative
- Proliferative Diabetic Retinopathy
United Kingdom Diabetic Retinopathy Market, By End User
- Hospitals & Eye Clinics
- Specialty Ophthalmology Center
- Ambulatory Surgical Centers
United Kingdom Diabetic Retinopathy Market, By Diagnostic Type
- Fundus Photography
- Optical Coherence Tomography (OCT)
- Fluorescein Angiography
- AI-Based Screening Tools
Expert Views:
The UK Diabetic Retinopathy Market is expected to expand steadily due to rising diabetes burden and strong NHS screening initiatives. Experts highlight that AI-based diagnostics and anti-VEGF therapies will remain central to treatment pathways. Continued innovation in long-acting drug delivery systems and tele-ophthalmology is expected to significantly improve early detection, treatment efficiency, and long-term vision preservation through 2035.